Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103)

PURPOSE: Bevacizumab improves progression-free survival but not overall survival in patients with metastatic breast cancer. E5103 tested the effect of bevacizumab in the adjuvant setting in patients with human epidermal growth factor receptor 2–negative disease. PATIENTS AND METHODS: Patients were a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Miller, Kathy D., O’Neill, Anne, Gradishar, William, Hobday, Timothy J., Goldstein, Lori J., Mayer, Ingrid A., Bloom, Stuart, Brufsky, Adam M., Tevaarwerk, Amye J., Sparano, Joseph A., Le-Lindqwister, Nguyet Anh, Hendricks, Carolyn B., Northfelt, Donald W., Dang, Chau T., Sledge, George W.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2018
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6118403/
https://ncbi.nlm.nih.gov/pubmed/30040523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.79.2028
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires